FML

What it isTopical glucocorticoid agonist; corticosteroid-responsive ocular inflammation.
Why this oneLimited corneal penetration tends to raise intraocular pressure less than prednisolone acetate but also limits potency.
What limits itProlonged use can still cause glaucoma and cataract; monitor pressure and reassess if deeper inflammation persists.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Steroid-responsive ocular inflammation | Ophthalmic | 1 drop into conjunctival sac 2–4×/day | 1 drop 2–4×/day | 1 drop q4h during initial 24–48 h |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Embryocidal and teratogenic in rabbits at low multiples of the ocular dose; use only if potential benefit justifies risk.
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.1 % | susp | per unit | not offered | |
| 0.25 % | susp | per unit | not offered |
Generic entryLong generic
NO BOXED WARNINGS
Principal riskSteroid-induced glaucoma and cataract on prolonged use
Legacy pregnancy categoryC
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.